See Also: U.S. Guidelines for HIV Testing, Prevention, and Treatment; Starting HIV Treatment; Comparing HIV Drug Regimens; Salvage Treatment for HIV; Innovative Approaches to HIV Treatment

Selected Recent Articles

• Ask A Pharmacist: With a new tenofovir, should you switch to Descovy, Genvoya or Odefsey?  (September 2016, Beta Blog)
• Kidney and Bone Markers Improve in Patients With Renal Impairment After Switch from TDF to TAF.  (August 2016, TheBodyPro)
• Studies examine switch to TAF-based regimens in patients with renal impairment.  (July 2016, Healio)
• Switch From TDF to TAF Tied to Better Bone Mineral Density and Bone Markers.  (July 2016, TheBodyPro)
• Integrase Inhibitors Work Well to Treat NNRTI Drug Resistant HIV.  (July 2016, Beta Blog)
• Nearly Two-Thirds Modify First-Line HIV Treatment Regimen in Large Study.  (April 2016, The BodyPro)
• Less Switching From Newer HIV Drug Combinations, and Better HIV Control.  (March 2016, HIV Treatment Alerts)
• Switching to Emtricitabine/Tenofovir Alafenamide (F/TAF) Maintains Viral Suppression with Better Bone and Kidney Safety.  (February 2016, TheBodyPro)
• People taking a large number of non-HIV-related medications more likely to stop or change HIV drugs.  (January 2016, AIDSmap)
• Switching to Abacavir/Dolutegravir/Lamivudine (Triumeq) Maintains Undetectable Viral Load.  (October 2015, TheBodyPro)
• HIV-positive patients in Africa do well on three second-line ART regimens.  (July 2015, AIDSmap)
• Second-line ART patients reach viral re-suppression following intensified adherence support.  (July 2015, AIDSmap)
• High treatment failure rate among Thai children switching to second-line ART.  (April 2015, AIDSmap)
• Pill A, Pill B: simplified second-line treatment for low-income countries. (August 2014, HIV i-Base)
• Time to first-line failure in the IeDEA cohort. (August 2014, HIV i-Base)
• Switching from first-line ART with suppressed viral load linked to treatment failure. (July 2014, AIDSmap)
• Dolutegravir demonstrates good efficacy despite resistance.  (July 2014, AIDSmap)
• DTG-Based Regimens Are Active in INI-Naive Patients With a History of NRTI Resistance.  (July 2014, NATAP)
• Effect of viral suppression below 20 copies of HIV-RNA /mL of plasma on virological outcome of treated HIV- infected patients.  (July 2014, NATAP)
• Failure Risk Similar With 20 to 50 Copies and Always Under 20 Copies.  (July 2014, NATAP)
• Good Response and Resistance Record in Naive and Experienced Starting Dolutegravir.  (July 2014, NATAP)
• Many People With HIV Could Switch to Newer, Safer Regimens.  (July 2014, Poz)
• Changing Meds May Be Unneeded After PI Treatment Failure.  (June 2014, Poz)
• People starting therapy on a boosted protease inhihibitor don’t need to switch after one virological failure episode, study indicates.  (June 2014, AIDSmap)
• FDA OKs Switching From Stable HIV Regimen to Complera.  (December 2013, Poz)
• Lipids Respond Well to Switch From Boosted PI to Rilpivirine/Tenofovir/Emtricitabine (Complera), Study Finds.  (October 2013, TheBodyPro)
• Costs Spike for 2nd- and 3rd-Line ARVs and Late Treatment.  (September 2013, Poz)
• Study supports WHO recommendations for second-line HIV therapy in resource-limited countries.  (July 2013, AIDSmap)
• Virologic Failure in 40% of Perinatally Infected US Children – Regimen Switching Slow.  (March 2013, NATAP)
• Can people with resistant HIV omit NRTIs when switching from a failing regimen?  (March 2013, AIDSmap)